CLINICAL RESEARCH: CLINICAL TRIAL
Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12 Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes
Robert F. Storey, MD*,1,*,
Steen Husted, MD ,1,
Robert A. Harrington, MD, FACC ,1,
Stanley Heptinstall, PhD ,1,
Robert G. Wilcox, MD,1,
Gary Peters, MD||,2,
Mark Wickens, BSc¶,2,
Håkan Emanuelsson, MD, PhD#,2,
Paul Gurbel, MD, FACC**,1,
Peer Grande, MD and
Christopher P. Cannon, MD, FACC,1
* Cardiovascular Research Unit, University of Sheffield, Sheffield, United Kingdom
Department of Medicine and Cardiology, Århus University Hospital, Århus, Denmark
Division of Cardiovascular Medicine, Duke Clinical Research Institute, Durham, North Carolina
Cardiovascular Medicine, University of Nottingham, Nottingham, United Kingdom
|| AstraZeneca R&D, Wilmington, Delaware
¶ AstraZeneca R&D, Charnwood, United Kingdom
# AstraZeneca R&D, Mölndal, Sweden
** Sinai Center for Thrombosis Research, Baltimore, Maryland
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts.
Manuscript received May 18, 2007;
revised manuscript received July 19, 2007,
accepted July 24, 2007.
* Reprint requests and correspondence: Dr. Robert F. Storey, Cardiovascular Research Unit, School of Medicine and Biomedical Sciences, Beech Hill Road, Sheffield S10 2RX, United Kingdom. (Email: r.f.storey{at}sheffield.ac.uk).
Objectives: In a substudy of DISPERSE (Dose confIrmation Study assessing anti-Platelet Effects of AZD6140 vs. clopidogRel in non–ST-segment Elevation myocardial infarction)-2, we compared the antiplatelet effects of AZD6140 and clopidogrel and assessed the effects of AZD6140 in clopidogrel-pretreated patients.
Background: Clopidogrel, in combination with aspirin, reduces cardiovascular events in patients with acute coronary syndromes (ACS). However, patients with poor inhibition of platelet aggregation with clopidogrel may be less well protected. AZD6140 is a reversible oral P2Y12 receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study).
Methods: Patients were randomized to receive either AZD6140 90 mg twice a day, AZD6140 180 mg twice a day, or clopidogrel 75 mg once a day for up to 12 weeks in a double-blind, double-dummy design. One-half the patients allocated AZD6140 received a 270-mg loading dose. Patients randomized to receive clopidogrel were given a 300-mg loading dose unless they had already been treated with clopidogrel. Adenosine diphosphate-induced platelet aggregation was assessed by optical aggregometry on day 1 and at 4-week intervals.
Results: AZD6140 inhibited platelet aggregation in a dose-dependent fashion and both doses achieved greater levels of inhibition than clopidogrel (e.g., 4 weeks, 4-h postdose [mean (±SD)]: clopidogrel 64% [±22%], AZD6140 90 mg 79% [±22%], AZD6140 180 mg 95% [±8%]. AZD6140 also produced further suppression of platelet aggregation in patients previously treated with clopidogrel.
Conclusions: AZD6140 exhibited greater mean inhibition of platelet aggregation than a standard regimen of clopidogrel in ACS patients. In addition, AZD6140 further suppressed platelet aggregation in clopidogrel pretreated patients.
|
Abbreviations and Acronyms
| | ACS = acute coronary syndromes | | ADP = adenosine diphosphate | | bid = twice-daily administration | | qd = once-daily administration |
|
This article has been cited by other articles:
|
|
|
|
 
L. Wallentin, R. C. Becker, A. Budaj, C. P. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, et al.
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
N. Engl. J. Med.,
September 10, 2009;
361(11):
1045 - 1057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Collet and G. Montalescot
Review: Platelet Function Testing and Implications for Clinical Practice
Journal of Cardiovascular Pharmacology and Therapeutics,
September 1, 2009;
14(3):
157 - 169.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Wallentin
P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use
Eur. Heart J.,
August 2, 2009;
30(16):
1964 - 1977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. SABATINE
Novel antiplatelet strategies in acute coronary syndromes
Cleveland Clinic Journal of Medicine,
April 1, 2009;
76(Suppl_1):
S8 - S15.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. H. Jeong, S.-W. Lee, B.-R. Choi, I.-S. Kim, M.-K. Seo, C. H. Kwak, J.-Y. Hwang, and S.-W. Park
Randomized Comparison of Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With High Post-Treatment Platelet Reactivity Results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) Randomized Study.
J. Am. Coll. Cardiol.,
March 31, 2009;
53(13):
1101 - 1109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cohen
Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care
Mayo Clin. Proc.,
February 1, 2009;
84(2):
149 - 160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Colombo and R. T. Gerber
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual Antiplatelet Therapy After Drug-Eluting Stents Should Not Be Continued for More Than 1 Year and Preferably Indefinitely
Circ Cardiovasc Interv,
December 1, 2008;
1(3):
226 - 232.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ferenc, M. Gick, R.-P. Kienzle, H.-P. Bestehorn, K.-D. Werner, T. Comberg, P. Kuebler, H. J. Buttner, and F.-J. Neumann
Randomized trial on routine vs. provisional T-stenting in the treatment of de novo coronary bifurcation lesions
Eur. Heart J.,
December 1, 2008;
29(23):
2859 - 2867.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. De Luca
Adjunctive antithrombotic therapy during primary percutaneous coronary intervention
Eur. Heart J. Suppl.,
December 1, 2008;
10(suppl_J):
J2 - J14.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Giugliano and E. Braunwald
The Year in Non-ST-Segment Elevation Acute Coronary Syndrome
J. Am. Coll. Cardiol.,
September 23, 2008;
52(13):
1095 - 1103.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Price
New antiplatelet therapies in development
Am. J. Health Syst. Pharm.,
July 1, 2008;
65(13_Supplement_5):
S11 - S15.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Storey
New developments in antiplatelet therapy
Eur. Heart J. Suppl.,
May 1, 2008;
10(suppl_D):
D30 - D37.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Kereiakes and P. A. Gurbel
Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention
J. Am. Coll. Cardiol. Intv.,
April 1, 2008;
1(2):
111 - 121.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the year in JACC 2007.
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. F. Storey
Variability of response to antiplatelet therapy
Eur. Heart J. Suppl.,
January 1, 2008;
10(suppl_A):
A21 - A27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Cannon, S. Husted, R. A. Harrington, B. M. Scirica, H. Emanuelsson, G. Peters, R. F. Storey, and for the DISPERSE-2 Investigators
Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: Primary Results of the DISPERSE-2 Trial
J. Am. Coll. Cardiol.,
November 6, 2007;
50(19):
1844 - 1851.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
